The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Assunta,Sgambato ^[1] ; Francesca,Casaluce ; Paolo,Maione ; Antonio,Rossi ; Emanuela,Rossi ; Alba,Napolitano ; Giovanni,Palazzolo ; Maria Anna,Bareschino ; Clorinda,Schettino ; Paola Claudia,Sacco ; Fortunato,Ciardiello ; Cesare,Gridelli

作者单位： Department of Clinical and Experimental Medicine, Second University of Naples, Italy. ^[1]

主题词动物(Animals);抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);药物设计(Drug Design);人类(Humans);肺肿瘤(Lung Neoplasms);分子靶向治疗(Molecular Targeted Therapy);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-met(Proto-Oncogene Proteins c-met);信号传导(Signal Transduction)

DOI 10.2174/138161212803582478

PMID 22873759

发布时间 2019-07-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览28

Current pharmaceutical design

2012年18卷37期

6155-68页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.

Current pharmaceutical design

相似文献

Current pharmaceutical design

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.

Current pharmaceutical design

相似文献

Current pharmaceutical design

相关期刊

检索历史清除